Table 1.
Patients’ characteristics and medical treatment
| Case 1 | Case 2 | Case 3 | Case 4 | |
| Age (years) | 47 | 36 | 44 | 35 |
| Sex | Female | Male | Female | Female |
| Risk factors | ||||
| Familial history | No | No | No | No |
| Hypertension | No | Yes | No | No |
| Hypercholesterolaemia | No | No | No | No |
| Diabetes | Type I | No | No | No |
| Smoking | No | No | No | Yes |
| History of other disease(s) | No | No | Heterozygous for prothrombin G20210A gene polymorphism | Varicose veins in the left leg |
| Leads with ST elevation at ECG on admission | V1–V5 | V2–V6 | V4–V6, DI, aVL | DII, DIII, aVF |
| Site of culprit lesion | Mid-LAD | Proximal LAD | Proximal LAD | Mid-RCA |
| Angiographic features of infarct related artery | ||||
| TIMI flow | 2 | 2 | 3 | 3 |
| Thrombus score | 3 | 2 | 2 | 3 |
| Antithrombotic treatment | ||||
| Acetylsalicylic acid (500 mg bolus intravenously followed by 250 mg/day orally) | Yes | Yes | Yes | Yes |
| rt-PA (before angiography) | Yes | Yes | No | No |
| Abciximab (bolus 0.25 mg/kg intravenously plus 12 hours infusion 0.125 mg/kg/min intravenously) | Yes | Yes | Yes | Yes |
| Unfractionated heparin (infusion for 48 hours followed by low molecular weight heparin subcutaneously for 15 days) | Yes | Yes | Yes | Yes |
| Clopidogrel (loading dose of 300 mg orally followed by 75 mg/day orally) | Yes | Yes | Yes | Yes |
LAD, left anterior descending artery; RCA, right coronary artery; rt-PA, recombinant tissue type plasminogen activator; TIMI, thrombolysis in myocardial infarction.